

## VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities



To effectively introduce vaccines to the market, sponsors depend on specialized vaccine-focused research sites and CROs to orchestrate clinical trials. These organizations offer comprehensive support throughout the process, managing tasks ranging from enlisting participants and ensuring regulatory adherence to gathering data, all within tighter schedules compared to conventional trials. As the worldwide vaccine market is projected to surpass \$65 billion by 2026, Contract Research Organizations (CROs) are enhancing their proficiency in vaccines to cater to the escalating need and capitalizing on the trend of outsourcing the management of clinical research sites.

Since 2012, VaxTRIALS has been involved in over 50 vaccine-related clinical,

epidemiological and health economics trials throughout the Latin American region. They are the largest vaccine focused CRO in the region with an active presence in 10+ countries. This market leading position made VaxTRIALS the ideal acquisition for Emmes to expand its vaccine clinical trial CRO capabilities.

Crosstree's expertise in the clinical research space and deep understanding of VaxTRIALS' unique value proposition helped the firm advise VaxTRIALS in identifying Emmes as the ideal transaction partner to allow them to grow their geographic footprint into the Latin American market and enhance their already market leading CRO capabilities.

**Crosstree helps clients articulate their unique value propositions and facilitates transactions with optimal, synergistic partners to accelerate growth & enhance value for all stakeholders**

## ABOUT VAXTRIALS



VaxTRIALS is a boutique clinical research organization (CRO) that provides innovative solutions in managing and monitoring vaccine clinical trial activities across Latin America. They use the highest quality standards to achieve and exceed their clients' expectations.

## ABOUT EMMES



Founded in 1977, Emmes is a global, full-service CRO dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company's clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical, and medical device companies throughout the world.

Emmes is a portfolio company of New Mountain Capital.

**CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:**

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

**MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.**

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



**JASON LAYTON**

Director

[jason.layton@crosstreecapital.com](mailto:jason.layton@crosstreecapital.com)

813-578-7109